CN104623607A - Traditional Chinese medicine composition for treating rheumatic and rheumatoid diseases - Google Patents
Traditional Chinese medicine composition for treating rheumatic and rheumatoid diseases Download PDFInfo
- Publication number
- CN104623607A CN104623607A CN201510060621.3A CN201510060621A CN104623607A CN 104623607 A CN104623607 A CN 104623607A CN 201510060621 A CN201510060621 A CN 201510060621A CN 104623607 A CN104623607 A CN 104623607A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- caulis
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to a traditional Chinese medicine composition for treating rheumatic and rheumatoid diseases. The traditional Chinese medicine composition comprises the following substances in parts by weight: 50-90 parts of panax pseudoginseng, 30-60 parts of olibanum, 30-60 parts of myrrh, 10-20 parts of semen strychni, 20-30 parts of stir-baked squama manitis, 20-60 parts of angelica sinensis, 20-60 parts of ligusticum wallichii, 20-60 parts of radix aconiti, 20-60 parts of radix aconiti agrestis, 30-90 parts of ground beetles, 30-90 parts of radix angelicae, 30-90 parts of safflowers, 15-30 parts of caulis akebiae, 30-50 parts of centipedes, 10-15 parts of scorpions, 30-90 parts of dipsacus roots, 60-90 parts of zaocys dhumnade, 30-60 parts of earthworms, 30-60 parts of caulis sinomenii, 30-60 parts of kadsura pepper stems, 30-60 parts of Chinese starjasmine stems and 60-90 parts of dried ginger. The traditional Chinese medicines in the composition disclosed by the invention are interacted to take a synergistic effect, and the composition is remarkable in curative effect so as to be very worthy of being powerfully popularized.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of Chinese medicine composition for the treatment of rheumatic and rheumatoid diseases.
Background technology
Rheumatoid arthritis, also known as rheumatoid, is the chronic systemic inflammation disease that a kind of cause of disease not yet understands, for main clinical manifestation, belongs to autoimmune inflammatory disease with pathological changes outside chronic, symmetry, many synovial jointss inflammation and joint.This disease is apt to occur in the Minor articulus such as hands, wrist, foot, and recurrent exerbation, is symmetric.Having joint red and swollen heat pain and dysfunction in early days, can there is stiff deformity in various degree in advanced joint, and with the atrophy of bone and bones flesh, very easily disables.The rheumatoid arthritis cause of disease is complicated, belongs to the traditional Chinese medical science " arthromyodynia " category.Numbness is that resistance closes obstructed meaning, the heresy that wind and cold is damp and hot, attacks human body in an opponent's defence, and cause QI-blood circulation not smooth, meridians are tired stagnant; Or phlegm-turbidity and blood stasis blood, hinder in meridians, go deep into joint muscle arteries and veins, all can fall ill.The generation of numbness disease also has substantial connection with the prosperity and decline of body constitution and weather conditions, living environment in addition.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine composition for the treatment of rheumatic and rheumatoid diseases.
In order to realize object of the present invention, the invention provides a kind of Chinese medicine composition for the treatment of rheumatic and rheumatoid diseases, it comprises the material of following weight portion: Radix Notoginseng 50-90 part, Olibanum 30-60 part, Myrrha 30-60 part, Semen Strychni 10-20 part, stir-baked SQUAMA MANITIS 20-30 part, Radix Angelicae Sinensis 20-60 part, Rhizoma Chuanxiong 20-60 part, Radix Aconiti 20-60 part, Radix Aconiti Kusnezoffii 20-60 part, Eupolyphaga Seu Steleophaga 30-90 part, Radix Angelicae Dahuricae 30-90 part, Flos Carthami 30-90 part, Caulis Akebiae 15-30 part, Scolopendra 30-50 part, Scorpio 10-15 part, Radix Dipsaci 30-90 part, Zaocys 60-90 part, Pheretima 30-60 part, Caulis Sinomenii 30-60 part, Caulis Piperis Kadsurae 30-60 part, Caulis Trachelospermi 30-60 part and Rhizoma Zingiberis 60-90 part.
Preferably, the Chinese medicine composition of described treatment rheumatic and rheumatoid diseases comprises the material of following weight portion: Radix Notoginseng 80 parts, Olibanum 50 parts, Myrrha 50 parts, Semen Strychni (processed) 10 parts, stir-baked SQUAMA MANITIS 25 parts, Radix Angelicae Sinensis 30 parts, Rhizoma Chuanxiong 50 parts, Radix Aconiti 20 parts, Radix Aconiti Kusnezoffii 20 parts, Eupolyphaga Seu Steleophaga 35 parts, the Radix Angelicae Dahuricae 50 parts, 60 parts, Flos Carthami, Caulis Akebiae 15 parts, Scolopendra 40 parts, Scorpio 10 parts, Radix Dipsaci 50 parts, Zaocys 70 parts, Pheretima 50 parts, Caulis Sinomenii 50 parts, Caulis Piperis Kadsurae 50 parts, Caulis Trachelospermi 50 parts and Rhizoma Zingiberis 80 parts.
Preferably, the Chinese medicine composition of described treatment rheumatic and rheumatoid diseases also comprises the material of following weight portion: Radix Berberidis 10 parts, Herba Lepisori Thunbergiani 15 parts, Herba Peristrophes 10 parts, 8 parts, three branch and leaf, large Oxalis corniculata Linn. 8 parts, raw 6 parts of mountain flower, Radix Berchemiae Yunnanensis 7 parts, Radix seu Caulis Schisandrae Sinensis 9 parts, 5 parts, sheep seven lotus, Herba Blumeae Lacerae 7 parts, Flos Hibisci Mutabilis 9 parts, pilea cadierei 7 parts and Radix et Rhizoma Iridis Sanguineae 8 parts.
Preferably, described Chinese medicine composition can be tablet, dispersible tablet, capsule, pill or medicated wine.
The present invention also provides the purposes of compositions in the Chinese medicine of preparation treatment rheumatic and rheumatoid diseases, described compositions comprises the material of following weight portion: Radix Notoginseng 50-90 part, Olibanum 30-60 part, Myrrha 30-60 part, Semen Strychni 10-20 part, stir-baked SQUAMA MANITIS 20-30 part, Radix Angelicae Sinensis 20-60 part, Rhizoma Chuanxiong 20-60 part, Radix Aconiti 20-60 part, Radix Aconiti Kusnezoffii 20-60 part, Eupolyphaga Seu Steleophaga 30-90 part, Radix Angelicae Dahuricae 30-90 part, Flos Carthami 30-90 part, Caulis Akebiae 15-30 part, Scolopendra 30-50 part, Scorpio 10-15 part, Radix Dipsaci 30-90 part, Zaocys 60-90 part, Pheretima 30-60 part, Caulis Sinomenii 30-60 part, Caulis Piperis Kadsurae 30-60 part, Caulis Trachelospermi 30-60 part and Rhizoma Zingiberis 60-90 part.
Preferably, described compositions comprises the material of following weight portion: Radix Notoginseng 80 parts, Olibanum 50 parts, Myrrha 50 parts, Semen Strychni (processed) 10 parts, stir-baked SQUAMA MANITIS 25 parts, Radix Angelicae Sinensis 30 parts, Rhizoma Chuanxiong 50 parts, Radix Aconiti 20 parts, Radix Aconiti Kusnezoffii 20 parts, Eupolyphaga Seu Steleophaga 35 parts, the Radix Angelicae Dahuricae 50 parts, 60 parts, Flos Carthami, Caulis Akebiae 15 parts, Scolopendra 40 parts, Scorpio 10 parts, Radix Dipsaci 50 parts, Zaocys 70 parts, Pheretima 50 parts, Caulis Sinomenii 50 parts, Caulis Piperis Kadsurae 50 parts, Caulis Trachelospermi 50 parts and Rhizoma Zingiberis 80 parts.
Preferably, described compositions also comprises the material of following weight portion: Radix Berberidis 10 parts, Herba Lepisori Thunbergiani 15 parts, Herba Peristrophes 10 parts, 8 parts, three branch and leaf, large Oxalis corniculata Linn. 8 parts, raw 6 parts of mountain flower, Radix Berchemiae Yunnanensis 7 parts, Radix seu Caulis Schisandrae Sinensis 9 parts, 5 parts, sheep seven lotus, Herba Blumeae Lacerae 7 parts, Flos Hibisci Mutabilis 9 parts, pilea cadierei 7 parts and Radix et Rhizoma Iridis Sanguineae 8 parts.
Preferably, described Chinese medicine can be tablet, dispersible tablet, capsule, pill or medicated wine.
Chinese medicine composition of the present invention interacts, and synergism is evident in efficacy, highly widelys popularize.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment 1 medicated wine of the present invention
Take Radix Notoginseng 80 grams, Olibanum 50 grams, Myrrha 50 grams, Semen Strychni (processed) 10 grams, stir-baked SQUAMA MANITIS 25 grams, Radix Angelicae Sinensis 30 grams, Rhizoma Chuanxiong 50 grams, Radix Aconiti 20 grams, Radix Aconiti Kusnezoffii 20 grams, Eupolyphaga Seu Steleophaga 35 grams, the Radix Angelicae Dahuricae 50 grams, 60 grams, Flos Carthami, Caulis Akebiae 15 grams, Scolopendra 40 grams, Scorpio 10 grams, Radix Dipsaci 50 grams, Zaocys 70 grams, Pheretima 50 grams, Caulis Sinomenii 50 grams, Caulis Piperis Kadsurae 50 grams, Caulis Trachelospermi 50 grams and Rhizoma Zingiberis 80 grams, add 4000 milliliters of dehydrated alcohol, dipping 7 days under the condition that room temperature is closed, filter, filtrate and get final product.
Embodiment 2 medicated wine of the present invention
Take Radix Notoginseng 80 grams, Olibanum 50 grams, Myrrha 50 grams, Semen Strychni (processed) 10 grams, stir-baked SQUAMA MANITIS 25 grams, Radix Angelicae Sinensis 30 grams, Rhizoma Chuanxiong 50 grams, Radix Aconiti 20 grams, Radix Aconiti Kusnezoffii 20 grams, Eupolyphaga Seu Steleophaga 35 grams, the Radix Angelicae Dahuricae 50 grams, 60 grams, Flos Carthami, Caulis Akebiae 15 grams, Scolopendra 40 grams, Scorpio 10 grams, Radix Dipsaci 50 grams, Zaocys 70 grams, Pheretima 50 grams, Caulis Sinomenii 50 grams, Caulis Piperis Kadsurae 50 grams, Caulis Trachelospermi 50 grams, Rhizoma Zingiberis 80 grams, Radix Berberidis 10 grams, Herba Lepisori Thunbergiani 15 grams, Herba Peristrophes 10 grams, three 8 grams, branch and leaf, large Oxalis corniculata Linn. 8 grams, raw 6 grams of mountain flower, Radix Berchemiae Yunnanensis 7 grams, Radix seu Caulis Schisandrae Sinensis 9 grams, 5 grams, sheep seven lotus, Herba Blumeae Lacerae 7 grams, Flos Hibisci Mutabilis 9 grams, pilea cadierei 7 grams and Radix et Rhizoma Iridis Sanguineae 8 grams, add 4000 milliliters of dehydrated alcohol, dipping 7 days under the condition that room temperature is closed, filter, filtrate and get final product.
Experimental example
Diagnostic criteria
With reference to the standard of Americanism damp disease association correction in 1987, its diagnostic criteria needs 7 in following project, and in 1-5 item, joint symptoms at least must continue 6 weeks.
(1) deadlock in morning (continuing more than I hour).
(2) pain or have tenderness (by doctor is seen) during at least one joint motion.
(3) at least one arthroncus (the plump or hydrops of soft tissue but not hyperosteogeny, by doctor is seen).
(4) at least another arthroncus (by doctor is seen, two joint involvement institute interludes should be no more than 3 months).
(5) symmetry arthroncus (by doctor is seen), invades the same joint (if not needing full symmetric when invading proximal phalangeal joints, metacarpophalangeal joints or toe joint) of body both sides simultaneously.Involving of distal interphalangeal joint can not meet this standard.
(6) bone protrusion or juxtra-articular stretch the subcutaneous nodule (by doctor is seen) of side.
(7) the X-ray film finding (outside deossification hypertrophy, the osteoporosis near affected joints must be had to exist) of standard.
(8) rheumatoid factor positive.
(9) in synovial fluid, mucin solidifies not good.
(10) have in following synovial membrane pathological change three or more: significantly fine hair hypertrophy; Top layer synovial cell proliferation and in paliform; Obvious chronic inflammation cell (being mainly lymphocyte and plasma cell) infiltrates and forms the trend of lymph node; Top layer or the interior fine and close fibrin deposition of interstitial; Focal necrosis.
(11) display centre district necrocytosis stove is answered by the Histological change in subcutaneous nodule, round macrophage and the outermost chronic inflammation cellular infiltration of palisade hypertrophy.
According to above-mentioned standard, select 60 routine rheumatic and rheumatoid patients, wherein man 30 example, female 30 example, age 25-63 year, average 41 years old.Be two groups by patient, be respectively treatment group 1 and treatment group 2, often group has 30 routine patients.Two groups of Genders, age, the course of disease, symptom there are no significant difference, have comparability (P > 0.05).
Treatment group 1 uses the medicated wine of preparation in embodiment 1 to treat, every day twice, and each gauze that uses dips 50 grams of medicated wine uniform application at arthritis pain sore spot, and wiping is generated heat slightly to skin, continuously treatment 2 months.
Treatment group 2 uses the medicated wine of preparation in embodiment 2 to treat, every day twice, and each gauze that uses dips 50 grams of medicated wine uniform application at arthritis pain sore spot, and wiping is generated heat slightly to skin, continuously treatment 2 months.
Criterion of therapeutical effect
According to wind and cold wet type arthromyodynia efficacy assessment standard relevant in the Chinese medical disease Standardization of diagnosis and curative effect of State Administration of Traditional Chinese Medicine's nineteen ninety-five issuing and implementation.
(1) clinical cure: arthralgia, swelling disappear, and movable function is normal, and lab testing is normal.
(2) take a turn for the better: arthralgia, swelling alleviate, movable function takes a turn for the better, and lab testing is improved.
(3) do not heal: arthralgia, swelling and lab testing are unchanged.
Statistical method
Utilize SPSS 13.0 software to process and analyze to experimental data, measurement data is with mean ± standard deviation
represent, adopt t inspection, enumeration data adopts x
2inspection, P < 0.05 represents that difference has statistical significance.
Result
Through treatment, for treatment group 1, clinical cure 11 example, take a turn for the better 13 examples, do not heal 6 examples, total effective rate is 80%, for treatment group 2, and clinical cure 18 example, take a turn for the better 10 examples, do not heal 2 examples, and total effective rate is that 93.3%, two groups of total effective rate comparing differences have statistical significance (P < 0.05).
Untoward reaction and toxic and side effects supervision
By detect patient blood pressure, pulse, whether there is Nausea and vomiting, dizzy clinical symptoms judges untoward reaction.Find that the systolic pressure of all patients is between 90-140mmHg, diastolic pressure is between 60-90mmHg, and pulse is 60-100 beat/min, and blood pressure and pulse all within normal range, and does not occur Nausea and vomiting, dizzy clinical symptoms.This illustrates that pharmaceutical composition of the present invention does not have obvious untoward reaction, and then proves that medicine does not have obvious toxic and side effects for human body.
Claims (8)
1. treat the Chinese medicine composition of rheumatic and rheumatoid diseases for one kind, it is characterized in that, it comprises the material of following weight portion: Radix Notoginseng 50-90 part, Olibanum 30-60 part, Myrrha 30-60 part, Semen Strychni 10-20 part, stir-baked SQUAMA MANITIS 20-30 part, Radix Angelicae Sinensis 20-60 part, Rhizoma Chuanxiong 20-60 part, Radix Aconiti 20-60 part, Radix Aconiti Kusnezoffii 20-60 part, Eupolyphaga Seu Steleophaga 30-90 part, Radix Angelicae Dahuricae 30-90 part, Flos Carthami 30-90 part, Caulis Akebiae 15-30 part, Scolopendra 30-50 part, Scorpio 10-15 part, Radix Dipsaci 30-90 part, Zaocys 60-90 part, Pheretima 30-60 part, Caulis Sinomenii 30-60 part, Caulis Piperis Kadsurae 30-60 part, Caulis Trachelospermi 30-60 part and Rhizoma Zingiberis 60-90 part.
2. the Chinese medicine composition for the treatment of rheumatic and rheumatoid diseases according to claim 1, it is characterized in that, it comprises the material of following weight portion: Radix Notoginseng 80 parts, Olibanum 50 parts, Myrrha 50 parts, Semen Strychni (processed) 10 parts, stir-baked SQUAMA MANITIS 25 parts, Radix Angelicae Sinensis 30 parts, Rhizoma Chuanxiong 50 parts, Radix Aconiti 20 parts, Radix Aconiti Kusnezoffii 20 parts, Eupolyphaga Seu Steleophaga 35 parts, the Radix Angelicae Dahuricae 50 parts, 60 parts, Flos Carthami, Caulis Akebiae 15 parts, Scolopendra 40 parts, Scorpio 10 parts, Radix Dipsaci 50 parts, Zaocys 70 parts, Pheretima 50 parts, Caulis Sinomenii 50 parts, Caulis Piperis Kadsurae 50 parts, Caulis Trachelospermi 50 parts and Rhizoma Zingiberis 80 parts.
3. the Chinese medicine composition for the treatment of rheumatic and rheumatoid diseases according to claim 1 and 2, it is characterized in that, it also comprises the material of following weight portion: Radix Berberidis 10 parts, Herba Lepisori Thunbergiani 15 parts, Herba Peristrophes 10 parts, 8 parts, three branch and leaf, large Oxalis corniculata Linn. 8 parts, raw 6 parts of mountain flower, Radix Berchemiae Yunnanensis 7 parts, Radix seu Caulis Schisandrae Sinensis 9 parts, 5 parts, sheep seven lotus, Herba Blumeae Lacerae 7 parts, Flos Hibisci Mutabilis 9 parts, pilea cadierei 7 parts and Radix et Rhizoma Iridis Sanguineae 8 parts.
4. the Chinese medicine composition for the treatment of rheumatic and rheumatoid diseases according to claim 3, is characterized in that, described Chinese medicine composition can be tablet, dispersible tablet, capsule, pill or medicated wine.
5. the purposes of compositions in the Chinese medicine of preparation treatment rheumatic and rheumatoid diseases, it is characterized in that, described compositions comprises the material of following weight portion: Radix Notoginseng 50-90 part, Olibanum 30-60 part, Myrrha 30-60 part, Semen Strychni 10-20 part, stir-baked SQUAMA MANITIS 20-30 part, Radix Angelicae Sinensis 20-60 part, Rhizoma Chuanxiong 20-60 part, Radix Aconiti 20-60 part, Radix Aconiti Kusnezoffii 20-60 part, Eupolyphaga Seu Steleophaga 30-90 part, Radix Angelicae Dahuricae 30-90 part, Flos Carthami 30-90 part, Caulis Akebiae 15-30 part, Scolopendra 30-50 part, Scorpio 10-15 part, Radix Dipsaci 30-90 part, Zaocys 60-90 part, Pheretima 30-60 part, Caulis Sinomenii 30-60 part, Caulis Piperis Kadsurae 30-60 part, Caulis Trachelospermi 30-60 part and Rhizoma Zingiberis 60-90 part.
6. purposes according to claim 5, it is characterized in that, described compositions comprises the material of following weight portion: Radix Notoginseng 80 parts, Olibanum 50 parts, Myrrha 50 parts, Semen Strychni (processed) 10 parts, stir-baked SQUAMA MANITIS 25 parts, Radix Angelicae Sinensis 30 parts, Rhizoma Chuanxiong 50 parts, Radix Aconiti 20 parts, Radix Aconiti Kusnezoffii 20 parts, Eupolyphaga Seu Steleophaga 35 parts, the Radix Angelicae Dahuricae 50 parts, 60 parts, Flos Carthami, Caulis Akebiae 15 parts, Scolopendra 40 parts, Scorpio 10 parts, Radix Dipsaci 50 parts, Zaocys 70 parts, Pheretima 50 parts, Caulis Sinomenii 50 parts, Caulis Piperis Kadsurae 50 parts, Caulis Trachelospermi 50 parts and Rhizoma Zingiberis 80 parts.
7. the purposes according to claim 5 or 6, it is characterized in that, described compositions also comprises the material of following weight portion: Radix Berberidis 10 parts, Herba Lepisori Thunbergiani 15 parts, Herba Peristrophes 10 parts, 8 parts, three branch and leaf, large Oxalis corniculata Linn. 8 parts, raw 6 parts of mountain flower, Radix Berchemiae Yunnanensis 7 parts, Radix seu Caulis Schisandrae Sinensis 9 parts, 5 parts, sheep seven lotus, Herba Blumeae Lacerae 7 parts, Flos Hibisci Mutabilis 9 parts, pilea cadierei 7 parts and Radix et Rhizoma Iridis Sanguineae 8 parts.
8. purposes according to claim 7, is characterized in that, described Chinese medicine can be tablet, dispersible tablet, capsule, pill or medicated wine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510060621.3A CN104623607B (en) | 2015-02-05 | 2015-02-05 | A kind of Chinese medicine composition for treating rheumatic and rheumatoid diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510060621.3A CN104623607B (en) | 2015-02-05 | 2015-02-05 | A kind of Chinese medicine composition for treating rheumatic and rheumatoid diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104623607A true CN104623607A (en) | 2015-05-20 |
| CN104623607B CN104623607B (en) | 2018-04-06 |
Family
ID=53203169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510060621.3A Active CN104623607B (en) | 2015-02-05 | 2015-02-05 | A kind of Chinese medicine composition for treating rheumatic and rheumatoid diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104623607B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770063A (en) * | 2016-05-17 | 2016-07-20 | 孙福强 | Traditional Chinese medicinal composition for treating rheumatoid disease |
| CN108392613A (en) * | 2018-05-08 | 2018-08-14 | 耿全好 | A kind of drug and preparation method thereof for treating cough |
| CN109248288A (en) * | 2018-11-28 | 2019-01-22 | 饶正军 | A kind of drug and preparation method thereof for treating rheumatism |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050089466A (en) * | 2004-03-05 | 2005-09-08 | 정진호 | Pharmaceutical compositions for treating rheumatism and method for production thereof |
| CN1785276A (en) * | 2005-11-08 | 2006-06-14 | 王显柱 | Medicine for treating atrophic arthritis |
| CN100998709A (en) * | 2007-01-05 | 2007-07-18 | 侯广建 | Plaster for treating pains on neck, shoulder, lumbar and legs |
| CN101474396A (en) * | 2009-02-06 | 2009-07-08 | 王晓敏 | Pharmaceutical composition for treating rheumatism and atrophic arthritis |
| CN101972453A (en) * | 2010-10-29 | 2011-02-16 | 韩世昌 | Chinese medicinal liquor for treating rheumatic and rheumatoid arthritis and preparation method thereof |
| CN103285202A (en) * | 2013-05-28 | 2013-09-11 | 刘绍峰 | Drug for treating rheumatism |
| CN103356854A (en) * | 2013-07-23 | 2013-10-23 | 董恩荣 | Traditional Chinese medicine for treating rheumatism |
-
2015
- 2015-02-05 CN CN201510060621.3A patent/CN104623607B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050089466A (en) * | 2004-03-05 | 2005-09-08 | 정진호 | Pharmaceutical compositions for treating rheumatism and method for production thereof |
| CN1785276A (en) * | 2005-11-08 | 2006-06-14 | 王显柱 | Medicine for treating atrophic arthritis |
| CN100998709A (en) * | 2007-01-05 | 2007-07-18 | 侯广建 | Plaster for treating pains on neck, shoulder, lumbar and legs |
| CN101474396A (en) * | 2009-02-06 | 2009-07-08 | 王晓敏 | Pharmaceutical composition for treating rheumatism and atrophic arthritis |
| CN101972453A (en) * | 2010-10-29 | 2011-02-16 | 韩世昌 | Chinese medicinal liquor for treating rheumatic and rheumatoid arthritis and preparation method thereof |
| CN103285202A (en) * | 2013-05-28 | 2013-09-11 | 刘绍峰 | Drug for treating rheumatism |
| CN103356854A (en) * | 2013-07-23 | 2013-10-23 | 董恩荣 | Traditional Chinese medicine for treating rheumatism |
Non-Patent Citations (3)
| Title |
|---|
| 李凤莲 等: "顽痹通治疗类风湿关节炎60例疗效观察", 《现代中西医结合杂志》 * |
| 王承德 等: "《实用中医风湿病学》", 31 May 1996, 人民卫生出版社 * |
| 黄道富 等: "蜈蚣龙蛇汤治疗类风湿性关节炎100 例", 《中国中医药信息杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770063A (en) * | 2016-05-17 | 2016-07-20 | 孙福强 | Traditional Chinese medicinal composition for treating rheumatoid disease |
| CN108392613A (en) * | 2018-05-08 | 2018-08-14 | 耿全好 | A kind of drug and preparation method thereof for treating cough |
| CN109248288A (en) * | 2018-11-28 | 2019-01-22 | 饶正军 | A kind of drug and preparation method thereof for treating rheumatism |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104623607B (en) | 2018-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104623607A (en) | Traditional Chinese medicine composition for treating rheumatic and rheumatoid diseases | |
| CN106511510A (en) | Medicine composition used for treating wind-cold-damp arthralgia and muscle and bone strain | |
| CN106039109A (en) | Traditional Chinese medicinal liquor for preventing and treating cold dampness accumulation pattern rheumatoid arthritis | |
| CN104689132A (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN104547936A (en) | Traditional Chinese medicine for treating local induration of vascular access of hemodialysis patient | |
| CN103908600A (en) | Externally-applied medicine for treating rheumatoid arthritis damp-heat blockage symptom as well as preparation method and administration method thereof | |
| CN104997890B (en) | A kind of Chinese materia medica preparation for treating fracture | |
| CN104491828B (en) | A kind of temperature leads to Traditional Chinese medicine used as analgesic preparation and its paste preparation method | |
| CN103316239A (en) | Traditional Chinese medicine for treating anaphylactoid purpura | |
| CN103768230B (en) | A kind of Chinese medicine fuming-lotion for the treatment of rheumatoid arthritis | |
| CN103705658B (en) | A kind of external traditional Chinese medicinal application for the treatment of rheumatoid arthritis | |
| CN105311473A (en) | Rapid hemostasis drug | |
| CN105412692A (en) | Traditional Chinese medicine preparation for treating arthroncus of knees | |
| CN104523879A (en) | Medicinal wine with effect of treating bone fracture and preparation method | |
| CN103751546A (en) | Traditional Chinese medicinal preparation for treating rheumatoid arthritis | |
| CN103705779B (en) | A kind of Chinese medicine composition treating contact dermatitis of face | |
| CN101385812B (en) | Traditional Chinese medicine composition containing epimeddium for treating dermatomyositis and preparation thereof | |
| CN101385805B (en) | Traditional Chinese medicine composition containing cicada-shell for treating dermatomyositis and preparation thereof | |
| CN103099861B (en) | Six rattans are drunk in treatment rheumatoid arthritis | |
| CN105434986A (en) | Traditional Chinese medicine preparation used for treating arthralgia | |
| CN1861119B (en) | Traditional Chinese medicine for treating rheumatosis and its preparation method | |
| CN104055865B (en) | A kind of Chinese medicine preparation for the treatment of the real pattern of fever chronic pancreatitis of stomach | |
| CN104840542A (en) | External lotion for curing ankle joint old tendon injury | |
| CN103263603B (en) | Medicine for treating arthralgia | |
| CN101385820B (en) | Traditional Chinese medicine composition containing ephedra for treating dermatomyositis and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |